Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
The Lancet. Infectious Diseases|February 15, 2021
QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trialKelly E Dooley, Susan L Rosenkranz, Francesca Conradie, et al.
American Journal of Respiratory and Critical Care Medicine|August 17, 2021
A Semimechanistic Model of the Bactericidal Activity of High-Dose Isoniazid against Multidrug-Resistant Tuberculosis: Results from a Randomized Clinical TrialKamunkhwala Gausi, Elisa H Ignatius, Xin Sun, et al.
The Journal of Antimicrobial Chemotherapy|June 9, 2022
Pharmacokinetics of standard versus high-dose isoniazid for treatment of multidrug-resistant tuberculosisKamunkhwala Gausi, Maxwell Chirehwa, Elisa H Ignatius, et al.
The Lancet. HIV|September 10, 2019
Antiretroviral therapy and vaginally administered contraceptive hormones: a three-arm, pharmacokinetic studyKimberly K Scarsi, Yoninah S Cramer, Susan L Rosenkranz, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 11, 2019
Pharmacokinetics and Pharmacodynamics of Depot Medroxyprogesterone Acetate in African Women Receiving Treatment for Human Immunodeficiency Virus and Tuberculosis: Potential Concern for Standard Dosing FrequencyRosie Mngqibisa, Michelle A Kendall, Kelly Dooley, et al.
Iscience|January 23, 2024
A novel macrolide-Del-1 axis to regenerate bone in old ageKridtapat Sirisereephap, Hikaru Tamura, Jong-Hyung Lim, et al.
The Lancet. HIV|October 2, 2015
Partner-based adherence intervention for second-line antiretroviral therapy (ACTG A5234): a multinational randomised trialRobert Gross, Lu Zheng, Alberto La Rosa, et al.
The Journal of Infectious Diseases|April 28, 2010
Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trialDavid M Asmuth, Robert L Murphy, Susan L Rosenkranz, et al.
American Journal of Respiratory and Critical Care Medicine|April 2, 2024
High-Dose Isoniazid Lacks EARLY Bactericidal Activity against Isoniazid-resistant Tuberculosis Mediated by katG Mutations: A Randomized Phase II Clinical TrialKamunkhwala Gausi, Elisa H Ignatius, Veronique De Jager, et al.
Clinical Pharmacology and Therapeutics|March 2, 2026
Clinical Pharmacology Quality Assurance Program for Global HIV and Co-Infection Drug DevelopmentRobin DiFrancesco, Troy D Wood, Raymond Cha, et al.
Pageof 7